The Efficacy and Safety of Muscle Relaxants in Inflammatory Arthritis: A Cochrane Systematic Review

REFERENCES

1. 1.↵
   1. Heiberg T,
   2. Kvien TK

   . Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: Pain has highest priority. Arthritis Rheum 2002;47:391–7.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Tak PP,
   2. Bresnihan B

   . The pathogenesis and prevention of joint damage in rheumatoid arthritis: Advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000;43:2619–33.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Kidd BL,
   2. Urban LA

   . Mechanisms of inflammatory pain. Br J Anaesth 2001;87:3–11.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Bolay H,
   2. Moskowitz MA

   . Mechanisms of pain modulation in chronic syndromes. Neurology 2002;59 Suppl 2:S2–7.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Wolfe F,
   2. Michaud K,
   3. Li T

   . Sleep disturbance in patients with rheumatoid arthritis: Evaluation by Medical Outcomes Study and visual analog sleep scales. J Rheumatol 2006;33:1942–51.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Morin CM,
   2. Gibson D,
   3. Wade J

   . Self-reported sleep and mood disturbance in chronic pain patients. Clin J Pain 1998;14:311–4.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Dickens C,
   2. McGowan L,
   3. Clark-Carter D,
   4. Creed F

   . Depression in rheumatoid arthritis: A systematic review of the literature with meta-analysis. Psychosom Med 2002;64:52–60.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Hagglund KJ,
   2. Haley WE,
   3. Reveille JD,
   4. Alarcon GS

   . Predicting individual differences in pain and functional impairment among patients with rheumatoid arthritis. Arthritis Rheum 1989;32:851–8.

   OpenUrlPubMed
9. 9.↵
   1. Smedstad LM,
   2. Vaglum P,
   3. Kvien TK,
   4. Moum T

   . The relationship between self-reported pain and sociodemographic variables, anxiety, and depressive symptoms in rheumatoid arthritis. J Rheumatol 1995;22:514–20.

   OpenUrlPubMed
10. 10.↵
    1. Smedstad LM,
    2. Moum T,
    3. Vaglum P,
    4. Kvien TK

    . The impact of early rheumatoid arthritis on psychological distress. A comparison between 238 patients with RA and 116 matched controls. Scand J Rheumatol 1996;25:377–82.

    OpenUrlPubMed
11. 11.↵
    1. Tobin JM,
    2. Lewis ND

    . New psychotherapeutic agent, chlordiazepoxide. Use in treatment of anxiety states and related symptoms. JAMA 1960;174:1242–9.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Randall LO,
    2. Heise GA,
    3. Schallek W,
    4. Bagdon RE,
    5. Banziger R,
    6. Boris A,
    7. et al.

    Pharmacological and clinical studies on Valium^™, a new psychotherapeutic agent of the benzodiazepine class. Curr Ther Res Clin Exp 1961;3:405–25.

    OpenUrlPubMed
13. 13.↵
    1. Waldman HJ

    . Centrally acting skeletal muscle relaxants and associated drugs. J Pain Symptom Manage 1994;9:434–41.

    OpenUrlPubMed
14. 14.↵
    1. Whittle SL,
    2. Colebatch AN,
    3. Buchbinder R,
    4. Edwards CJ,
    5. Adams K,
    6. Englbrecht M,
    7. et al.

    Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: Integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology 2012 Mar 24. [Epub ahead of print]
15. 15.↵
    1. Richards BL,
    2. Whittle SL,
    3. Buchbinder R

    . Muscle relaxants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev 2012;1:CD008922.

    OpenUrlPubMed
16. 16.↵
    1. Higgins JP,
    2. Green S

    , editors. Cochrane handbook for systematic reviews of interventions, Version 5.0.2 (updated September 2009). The Cochrane Collaboration; 2009.
17. 17.↵
    1. Sackett DL,
    2. Richardson WS,
    3. Rosenberg WM,
    4. Haynes RB

    . Evidence-based medicine: How to practice and teach EBM. London, UK: Churchill Livingstone; 1997.
18. 18.↵
    1. Higgins JP,
    2. Green S

    1. Deeks JJ,
    2. Higgins JP,
    3. Altman DG

    , editors. ObotCSMG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions, Version 502 (updated September 2009). The Cochrane Collaboration; 2009.
19. 19.↵
    1. Bayley TR,
    2. Haslock I

    . Night medication in rheumatoid arthritis. J R Coll Gen Pract 1976;26:591–4.

    OpenUrlPubMed
20. 20.↵
    1. Hobkirk D,
    2. Rhodes M,
    3. Haslock I

    . Night medication in rheumatoid arthritis: II. Combined therapy with indomethacin and diazepam. Rheumatol Rehabil 1977;16:125–7.

    OpenUrlPubMed
21. 21.↵
    1. Sharma BK,
    2. Haslock I

    . Night medication in rheumatoid arthritis. III. the use of sulindac. Curr Med Res Opin 1978;5:472–5.

    OpenUrlPubMed
22. 22.↵
    1. Vince JD,
    2. Kremer D

    . Double-blind trial of diazepam in rheumatoid arthritis. Practitioner 1973;210:264–7.

    OpenUrlPubMed
23. 23.↵
    1. Walsh JK,
    2. Muehlbach MJ,
    3. Lauter SA,
    4. Hilliker NA,
    5. Schweitzer AK

    . Effects of triazolam on sleep, daytime sleepiness and morning stiffness in patients with rheumatoid arthritis. J Rheumatol 1996;23:245–52.

    OpenUrlPubMed
24. 24.↵
    1. Drewes AM,
    2. Bjerregard K,
    3. Taagholt SJ,
    4. Svendsen L,
    5. Nielsen KD

    . Zopiclone as night medication in rheumatoid arthritis. Scand J Rheumatol 1998;27:180–7.

    OpenUrlCrossRefPubMed